Pembrolizumab (Pembro; Mk-3475) for Advanced Melanoma (Mel): Randomized Comparison of Two Dosing SchedulesCaroline Robert, Omid Hamid, W. Hwu et al.|Annals of Oncology|2014Cited by 23
Pembrolizumab plus ipilimumab for advanced melanoma : results of the keynote-029 expansion cohortGeorgina V. Long, John A. Thompson, Atkinson et al.|Unknown|2016Cited by 8
140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)Adil Daud, A. Ribas, Omid Hamid et al.|European Journal of Cancer|2014Cited by 6
Randomized comparison of two doses of the anti-programmed death-1 monoclonal antibody MK-3475 for ipilimumab (IPI)-refractory and IPI-naive melanomaRichard Kefford, Adil Daud, Omid Hamid et al.|Unknown|2014Cited by 0